Ads
related to: psa 0.2 2 years after radical prostatectomy- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Prostate Cancer Treatment
Search results
Results From The WOW.Com Content Network
The risk of disease progression and metastasis (spread of the cancer) may be increased, but this increase risk appears to be small if the program of surveillance is followed closely, generally including serial PSA assessments and repeat prostate biopsies every 1–2 years depending on the PSA trends. [medical citation needed]
Men with prostate cancer whose PSA level increased by more than 2.0 ng per milliliter during the year before the diagnosis of prostate cancer have a higher risk of death from prostate cancer despite undergoing radical prostatectomy. [62] PSA velocity (PSAV) was found in a 2008 study to be more useful than the PSA doubling time (PSA DT) to help ...
A significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs ...
The 4Kscore combines total, free and intact PSA together with human kallikrein 2. [46] It is used to try to determine the risk of a Gleason score greater than 6. [46] The Prostate Health Index (PHI) is a PSA-based blood test for early prostate cancer screening. It may be used to determine when a biopsy is needed.
Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. [1] It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality.
In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells. [19] Because of this high expression, PSMA is being developed as potential biomarker for therapy and imaging of some cancers. [ 20 ]